Jul 30, 2026, 13:00 UTC
The Arkansas State Board of Pharmacy voted on July 30, 2026 to suspend enforcement of Act 630 of 2025, a law that would have prevented drugmakers from limiting which pharmacies can purchase their drugs, after a federal judge ruled the law unconstitutional.
Source:Jul 21, 2026, 05:00 UTC
Novartis AG reported second-quarter core earnings per share of $2.41 and net sales of $14.41 billion.
Jul 17, 2026, 19:26 UTC
Novartis receives full FDA approval for Fabhalta in IgA nephropathy.
Source:Jul 16, 2026, 12:00 UTC
Novartis promoted Pankhuri Garg to director of talent and development, effective immediately.
Source:Jul 15, 2026, 05:00 UTC
Chai Discovery announced a collaboration agreement with Novartis.
Source:Jul 6, 2026, 05:05 UTC
Novartis has agreed to acquire Myricx Bio for up to $1.5 billion.
Jul 2, 2026, 05:57 UTC
The European Commission approved Novartis's Itvisma for the treatment of spinal muscular atrophy in a broad population.
Jul 1, 2026, 03:32 UTC
Anthropic announced an in-house drug discovery project targeting neglected diseases, entering the healthtech space.
Source:Jun 30, 2026, 22:45 UTC
Novartis and Antares have signed an agreement for cancer small molecules.
Source:Jun 24, 2026, 11:00 UTC
Antares Therapeutics entered a strategic collaboration agreement with Novartis to discover, develop and commercialize small molecule therapies against oncology targets.
Source:Jun 23, 2026, 19:51 UTC
Novartis AG reported that its experimental drug del-brax, acquired through the Avidity Biosciences deal, showed promise in an early to mid-stage study for facioscapulohumeral muscular dystrophy.
Source:Jun 23, 2026, 19:51 UTC
Novartis AG reported early data from an actinium-based radiopharma drug showing anti-tumor activity in advanced prostate cancer.
Source:Jun 19, 2026, 08:07 UTC
Amgen India appointed Anjali Rao as executive director of human resources.
Source:Jun 18, 2026, 11:58 UTC
Curium prevailed in a patent dispute brought by Novartis subsidiary Advanced Accelerator Applications in the Delaware U.S. District Court, with all relevant patent claims ruled invalid and not infringed.
Source:Jun 15, 2026, 15:30 UTC
Novartis reports that its drug Rhapsido met the primary goal in a Phase III study for chronic inducible urticaria, supporting new regulatory filings.
Source:Jun 11, 2026, 21:41 UTC
Novartis acquired Avidity as part of a $12 billion takeover.
Source:Jun 11, 2026, 05:00 UTC
Novartis announced that its del-brax Phase I/II study in FSHD met its primary biomarker endpoint, indicating potential for a first disease-modifying treatment.
Jun 10, 2026, 11:00 UTC
Orionis Biosciences announced a multi-year strategic collaboration with Novartis to discover and develop molecular glue medicines.
Source:
← PreviousPage 2